Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NewAmsterdam Pharma Company NV | NAMSW | NASDAQ | Equity Warrant |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.78 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.78 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 14.78 | USD |
NewAmsterdam Pharma Company NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.22B | 82.47M | - | 14.09M | -176.94M | -2.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News NewAmsterdam Pharma Comp...
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
NAMSW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. |
NASDAQ:NAMSW -
What is the current NewAmsterdam Pharma Company NV share price?
The current share price of NewAmsterdam Pharma Company NV is $ 14.78
How many NewAmsterdam Pharma Company NV shares are in issue?
NewAmsterdam Pharma Company NV has 82,470,000 shares in issue
What is the market cap of NewAmsterdam Pharma Company NV?
The market capitalisation of NewAmsterdam Pharma Company NV is USD 1.22B
What is the 1 year trading range for NewAmsterdam Pharma Company NV share price?
NewAmsterdam Pharma Company NV has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the PE ratio of NewAmsterdam Pharma Company NV?
The price to earnings ratio of NewAmsterdam Pharma Company NV is -11.91
What is the cash to sales ratio of NewAmsterdam Pharma Company NV?
The cash to sales ratio of NewAmsterdam Pharma Company NV is 149.5
What is the reporting currency for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV reports financial results in USD
What is the latest annual turnover for NewAmsterdam Pharma Company NV?
The latest annual turnover of NewAmsterdam Pharma Company NV is USD 14.09M
What is the latest annual profit for NewAmsterdam Pharma Company NV?
The latest annual profit of NewAmsterdam Pharma Company NV is USD -176.94M
What is the registered address of NewAmsterdam Pharma Company NV?
The registered address for NewAmsterdam Pharma Company NV is GOOIMEER 2-35, NAARDEN, NORTH HOLLAND, 1411 DC
What is the NewAmsterdam Pharma Company NV website address?
The website address for NewAmsterdam Pharma Company NV is www.newamsterdampharma.com
Which industry sector does NewAmsterdam Pharma Company NV operate in?
NewAmsterdam Pharma Company NV operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
